紫杉醇亚微球制备及治疗小鼠乳腺癌的实验研究  

Experimental study on paclitaxol-PCL nanoparticles in mouse breast cancer

作　　者：鲍滨[1] 杨菁[1] 党丽捷[1] 宋存先[1] 

机构地区：[1]中国医学科学院生物医学工程研究所,天津300192

出　　处：《生物医学工程与临床》2007年第3期174-178,F0003,共6页Biomedical Engineering and Clinical Medicine

基　　金：国家自然科学基金(50473059);博士点基金(20030023004);天津市自然科学基金(05YFJMJC10100;043803011)

摘　　要：目的观察紫杉醇亚微球对小鼠乳腺癌的治疗效果。方法以可生物降解材料聚己内酯(poly-caprolacton,PCL)为原料,采用溶剂替代法制备载紫杉醇亚微球。并对亚微球的粒径、形态、紫杉醇含量、体外释放等进行了测定。将TA2系实验小鼠随机分为空白对照组、紫素阳性对照组、紫杉醇亚微球低剂量组、紫杉醇亚微球中剂量组及紫杉醇亚微球高剂量组。实验时分别将生理盐水、紫素、紫杉醇亚微球注射到小鼠乳腺癌部位,通过测量治疗前后肿瘤大小,观察紫杉醇亚微球治疗实验小鼠乳腺癌的效果。结果制备的紫杉醇亚微球的平均粒径约为566nm,包埋率为93.25%,亚微球中紫杉醇含量约19.0536%。可在体外维持恒定释放约4周。药物注射2周观察抑瘤率:紫杉醇亚微球中剂量组为70.21%,紫杉醇亚微球高剂量组为84.16%,与紫素阳性对照组(48.96%)比较差异有显著统计学意义(P<0.001)。紫杉醇亚微球低剂量组为45.47%,与紫素阳性对照组相比,两者差异亦有显著统计学意义(P<0.001)。结论紫杉醇亚微球(中剂量组和高剂量组)对小鼠乳腺癌的抑瘤率高于紫素。Objective To study the therapeutic efficacy of paclitaxel-PCL nanoparticles in mouse breast cancer. Methods A biodegradable poly-caprolacton （PCL） was adopted as drug delivery material. Paclitaxel drug delivery nanoparticles （NP） were prepared by a multi-emulsification technique. The nanoparticles were characterized for size, drug loading capacity, and in vitro release. The experimental mice were randomly divided into vacant control group, paclitaxel positive control group, Paclitaxel-NP low-dose group, Paclitaxel-NP meta-dose group and Paclitaxel-NP high dose group. Paclitaxel or Paclitaxel-NP was injected into mouse breast cancer,then the tumor size was measured. Results The average size of Paclitaxel-NP was around 300 nm. The encapsulation efficiency of Paclitaxel was above 96 %. Loading amount of Paclitaxel in the nanoparticles was about 4 %. In vitro ,nanoparticles maintained sustaining release of Paclitaxel for 2 weeks. After 2 week ,the inhibition ratio of tumor growth in Paclitaxel-NP meta-dose group was 70.21% ,in Paclitaxel-NP high dose group was 84.16 % ,in Paclitaxel positive control group was 48.96 %. The differences of both groups compared with control were significant （P 〈 0.001 ） ;in Paclitaxel-NP low-dose group was 45.4 % ,showing was significant difference compared with control （P 〈 0.001 ）. Conclusion The inhibition ratio of tumor growth in Paclitaxel-NP （meta-dose group and high dose group） is higher than that in paclitaxel group.

关 键 词：紫杉醇 PCL亚微球 小鼠 乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]